Syndax Pharmaceuticals IncSNDX
| Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 |
---|
Net income (loss) | - | - | -74 | -56 | -73 | 25 | -149 |
---|
Depreciation | - | - | - | - | 0 | 0 | 0 |
---|
(Accretion) and Amortization of investments | 0 | -0 | 1 | 1 | 0 | -1 | 3 |
---|
Noncash Operating Lease Expense | - | - | - | 0 | 0 | 0 | 0 |
---|
Non-cash interest expense | - | - | - | - | - | -0 | 1 |
---|
Changes in fair value of derivative liability | - | - | - | - | - | 0 | 0 |
---|
Stock-based compensation | 5 | 5 | 6 | 6 | 9 | 13 | 16 |
---|
Other | -0 | -0 | -0 | - | -0 | 0 | - |
---|
Prepaid expenses and other assets | 2 | 0 | -1 | 0 | 4 | 1 | 3 |
---|
Collaboration receivable, net | - | - | - | - | - | - | -3 |
---|
Accounts payable | 1 | -0 | -1 | 5 | -3 | 2 | -1 |
---|
Deferred revenue | - | - | -2 | -2 | -2 | -13 | - |
---|
Accrued expenses and other liabilities | 5 | 5 | 1 | -3 | 1 | 3 | 9 |
---|
Net cash provided by (used in) operating activities | - | - | -69 | -51 | -71 | 29 | -134 |
---|
Purchases of property and equipment | 0 | 0 | 0 | - | - | 0 | - |
---|
Proceeds from Sale of Machinery and Equipment | - | - | - | - | - | - | 0 |
---|
Purchases of short-term investments | 158 | 152 | 79 | 104 | 279 | 295 | 495 |
---|
Proceeds from sales and maturities of short-term investments | 140 | 135 | 130 | 117 | 136 | 254 | 309 |
---|
Net cash used in investing activities | - | - | 51 | 13 | -143 | -41 | -186 |
---|
Follow-on Public Offerings | - | - | - | - | 243 | 81 | 162 |
---|
At-the-Market Offering | - | 2 | 15 | 1 | - | 5 | 19 |
---|
Derivative Liability | - | - | - | - | - | 1 | - |
---|
Private Placement | - | 25 | - | 27 | 35 | - | - |
---|
Payment on term loan | - | - | - | - | - | - | 21 |
---|
Proceeds from term loan agreement, net | - | - | - | - | 20 | - | - |
---|
Proceeds from ESPP | - | 0 | 0 | 0 | 0 | 0 | 0 |
---|
Proceeds from stock option exercises | 2 | 0 | 26,000 | 178,000 | 7 | 6 | 12 |
---|
Other | -0 | - | 0 | - | 0 | - | - |
---|
Net cash provided by financing activities | - | - | 16 | 29 | 304 | 118 | 172 |
---|
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | - | - | -1 | -9 | 91 | 107 | -148 |
---|